[低风险骨髓增生异常肿瘤的新治疗策略]。

Yasuyoshi Morita
{"title":"[低风险骨髓增生异常肿瘤的新治疗策略]。","authors":"Yasuyoshi Morita","doi":"10.11406/rinketsu.66.581","DOIUrl":null,"url":null,"abstract":"<p><p>The goal of treatment for lower-risk myelodysplastic neoplasms (MDS) is to improve cytopenia, and therapeutic options should include agents with few adverse events. Since anemia is the main symptom of this disease, red blood cell transfusions, darbepoetin, anabolic steroids, and immunosuppressive agents are considered when the disease is symptomatic, but with the advent of the novel anti-anemic agent luspatercept, there is growing debate regarding the timing of therapeutic intervention and the hemoglobin (Hb) levels at which red blood cell transfusion should be considered in this disease. As a result, there is a growing debate among institutions regarding these issues. It has become clear that there are slight differences in the criteria for initiation of transfusion and the timing of therapeutic intervention with anti-anemic agents at different centers. In this review, we will discuss the extent to which therapeutic intervention for lower-risk MDS improves the quality of life (QOL) of patients and how to improve the efficiency of limited healthcare resources, including an overview of ongoing clinical trials.</p>","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 7","pages":"581-589"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Novel treatment strategies for lower-risk myelodysplastic neoplasms].\",\"authors\":\"Yasuyoshi Morita\",\"doi\":\"10.11406/rinketsu.66.581\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The goal of treatment for lower-risk myelodysplastic neoplasms (MDS) is to improve cytopenia, and therapeutic options should include agents with few adverse events. Since anemia is the main symptom of this disease, red blood cell transfusions, darbepoetin, anabolic steroids, and immunosuppressive agents are considered when the disease is symptomatic, but with the advent of the novel anti-anemic agent luspatercept, there is growing debate regarding the timing of therapeutic intervention and the hemoglobin (Hb) levels at which red blood cell transfusion should be considered in this disease. As a result, there is a growing debate among institutions regarding these issues. It has become clear that there are slight differences in the criteria for initiation of transfusion and the timing of therapeutic intervention with anti-anemic agents at different centers. In this review, we will discuss the extent to which therapeutic intervention for lower-risk MDS improves the quality of life (QOL) of patients and how to improve the efficiency of limited healthcare resources, including an overview of ongoing clinical trials.</p>\",\"PeriodicalId\":93844,\"journal\":{\"name\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"volume\":\"66 7\",\"pages\":\"581-589\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"[Rinsho ketsueki] The Japanese journal of clinical hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11406/rinketsu.66.581\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.66.581","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

低风险骨髓增生异常肿瘤(MDS)的治疗目标是改善细胞减少症,治疗方案应包括不良事件少的药物。由于贫血是本病的主要症状,当疾病出现症状时,考虑输注红细胞、达贝泊丁、合成代谢类固醇和免疫抑制剂,但随着新型抗贫血药物luspatercept的出现,关于治疗干预的时机和血红蛋白(Hb)水平的争论越来越多,在这种疾病中应该考虑输注红细胞。因此,各机构之间就这些问题展开了越来越多的辩论。很明显,在不同的中心,开始输血的标准和抗贫血药物治疗干预的时间有细微的差异。在这篇综述中,我们将讨论低风险MDS的治疗干预在多大程度上改善了患者的生活质量(QOL),以及如何提高有限医疗资源的效率,包括对正在进行的临床试验的概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Novel treatment strategies for lower-risk myelodysplastic neoplasms].

The goal of treatment for lower-risk myelodysplastic neoplasms (MDS) is to improve cytopenia, and therapeutic options should include agents with few adverse events. Since anemia is the main symptom of this disease, red blood cell transfusions, darbepoetin, anabolic steroids, and immunosuppressive agents are considered when the disease is symptomatic, but with the advent of the novel anti-anemic agent luspatercept, there is growing debate regarding the timing of therapeutic intervention and the hemoglobin (Hb) levels at which red blood cell transfusion should be considered in this disease. As a result, there is a growing debate among institutions regarding these issues. It has become clear that there are slight differences in the criteria for initiation of transfusion and the timing of therapeutic intervention with anti-anemic agents at different centers. In this review, we will discuss the extent to which therapeutic intervention for lower-risk MDS improves the quality of life (QOL) of patients and how to improve the efficiency of limited healthcare resources, including an overview of ongoing clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信